Loading...
XNAS
PRME
Market cap661mUSD
Dec 05, Last price  
3.74USD
1D
-2.86%
1Q
0.54%
IPO
-76.27%
Name

Prime Medicine Inc

Chart & Performance

D1W1MN
XNAS:PRME chart
P/E
P/S
221.92
EPS
Div Yield, %
Shrs. gr., 5y
4.38%
Rev. gr., 5y
%
Revenues
3m
05,210,0000002,983,000
Net income
-196m
L-1.14%
-2,529,000-3,410,000-165,367,000-121,821,000-198,133,000-195,882,000
CFO
-123m
L-25.72%
-1,334,000-5,544,000-34,082,000-131,827,000-165,412,000-122,865,000
Dividend
Sep 10, 20190.8 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
IPO date
Oct 20, 2022
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT